1. Home
  2. EDBL vs SCNI Comparison

EDBL vs SCNI Comparison

Compare EDBL & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

N/A

Current Price

$2.94

Market Cap

1.8M

ML Signal

N/A

SCNI

Scinai Immunotherapeutics Ltd.

N/A

Current Price

$0.77

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDBL
SCNI
Founded
2020
2003
Country
United States
Israel
Employees
99
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EDBL
SCNI
Price
$2.94
$0.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
75.3K
51.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.56
N/A
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.61
52 Week High
$7.54
$6.18

Technical Indicators

Market Signals
Indicator
EDBL
SCNI
Relative Strength Index (RSI) 54.05 41.24
Support Level $2.49 $0.65
Resistance Level $4.15 $0.94
Average True Range (ATR) 0.27 0.09
MACD -0.14 -0.00
Stochastic Oscillator 35.40 16.06

Price Performance

Historical Comparison
EDBL
SCNI

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: